Keytruda trial for untreated lymphoma halted early
NCT ID NCT03498612
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II study tested the immunotherapy drug pembrolizumab (Keytruda) in 9 people with untreated follicular lymphoma or marginal zone lymphoma. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was terminated early, so we have very little data on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda)
- What this could lead to
- If it had succeeded, this could have pointed toward an immunotherapy option for untreated follicular and marginal zone lymphoma, potentially delaying the need for chemotherapy.
- What could go wrong
- The trial was terminated early with only 9 participants, so results are very limited. Pembrolizumab can cause immune-related side effects, and it is unclear if it works as a first treatment for these lymphomas.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug beat radiation for early-stage lymphoma?